- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02451527
The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects
November 28, 2016 updated by: First Affiliated Hospital Xi'an Jiaotong University
An Open-label,Single-arm,Sequential,Single-center Clinical Trial of the Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection (PEX168) in Healthy Adult Subjects
The purpose of this study is to evaluate the pharmacokinetic study of the combination of digoxin and polythylene glycol loxenatide injection (PEX168) in healthy adults,and to provide scientific basis for clinical combination of PEX168 and drugs.This study is also to evaluate the safety and tolerability of mono-digoxin or digoxin plus PEX168.
Study Overview
Detailed Description
This will be an open-label, single-arm, sequential, single-center clinical trial.
16 healthy males will be admitted to the clinical facility on Day -1, the day prior to the start of dosing.
The subjects will be observed in clinic twice: Day -1 to 8 and Day 37 to 44.
Subjects will receive a single dose of digoxin on Day 1 followed by 5 weekly subcutaneously injected doses of PEX168 and a second single dose of digoxin on Day 38.
To determine the pharmacokinetic parameters of digoxin after drug administration alone and after multiple doses of PEX168, blood and urine samples will be collected after each dose of digoxin and tested by the laboratory.The subjects will be discharged on Day 8 and Day 44.
Approximately 28 days after the last discharge, the subjects will be called for a post study visit.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shaanxi
-
Xian, Shaanxi, China, 710061
- The First Affiliated Hospital of Xi'An JiaoTong University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy males aged from 18 to 45 years
- Have a body weight over 50kg, have a body mass index (BMI) 19-25 kg/m^2 (both inclusive)
- Alanine aminotransferase<50 U/L, aspartate aminotransferase<50 U/L, alkaline phosphatase and total bilirubin <1.5x the upper limit of normal
- According to Cockcroft-Gault, estimated Clcr≥90ml/min
- Able to comprehend and willing to sign the informed consent form
Exclusion Criteria:
- Hepatitis B surface antigen(+), Hepatitis C virus antibody(+),AIDS antibody(+)
- History of syncope, palpitations, bradycardia and tachycardia (for example any degree of atrioventricular block, left bundle branch block, right bundle branch block), or have an abnormal result of overall physical examination (vital signs, physical examination), routine laboratory assessment (hematology, biochemistry and urinalysis), 12-lead ECG and abdominal sonography (liver, gallbladder, pancreas, spleen, kidney)
- Have had an alcohol and substance abuse within 6 months of screening
- History of smoking within 3 months of screening
- BP>140/90 millimetres of mercury, or heart rate >100 bpm
- QT interval >450ms
- History of drug-induced allergy or of hypersensitivity for digoxin and PEX168
- History of serious heart disease or lung disease
- Fasting triglyceride>1.5x the upper limit of normal
- Subjects with liver disease or have history of liver disease or abnormal liver and gallbladder conditions
- Donation of blood in excess of 400 mL within the 3 months of screening; or donation of blood within 1 month of screening; or received blood transfusions within 1 month of screening.
- Hypothyroidism
- Surgery of gastrointestinal tract
- History of pancreatitis
- History of cholecystitis or other gallbladder disease
- History of inflammatory bowel disease or irritable bowel syndrome
- History of MEN type 2 syndrome
- History of medullary thyroid carcinoma
- A family history of MEN type 2 syndrome and medullary thyroid carcinoma
- Have participated in clinical trials with drug or medical devices involved within 3 months of screening
- Have received any drug that may affect the study drugs within 2 weeks of screening, including prescribed drugs, over-counted drugs, Chinese traditional medicine or multivitamins
- History of grapefruit juice, cranberry, mango, foods and drinks of xanthine or caffeine, strenuous exercise, or any other factor affect the absorption, distribution, metabolism and excretion of the study drug within 2 days of screening
- Have received any glucagon-like peptide-1 mimetic compound(e.g., exenatide)
- Have been disagreed to use a reliable method of birth control during the study and for 6 months following the last dose of study drug
- History of any other condition, which in the opinion of the investigator, may prevent the subject from following and completing the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Digoxin and PEX168
A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of a single dose of 200ug PEX168, followed by a further single dose of 0.5mg digoxin on Day 38.
|
Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
Other Names:
PEX168 in subcutaneous injection on Day8,15,22,29 and Day 36
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of pharmacokinetic (PK) parameters of digoxin with and without PEX168 in plasma and urine (cmax, t 1/2)
Time Frame: Day 1 through Day 44
|
Maximum observed concentration in plasma(cmax); apparent terminal elimination half-life in plasma(t1/2).
|
Day 1 through Day 44
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: Day 1 through Day 44
|
Day 1 through Day 44
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Bingyin Shi, MD, First Affiliated Hospital Xi'an Jiaotong University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
July 1, 2016
Study Registration Dates
First Submitted
May 12, 2015
First Submitted That Met QC Criteria
May 21, 2015
First Posted (Estimate)
May 22, 2015
Study Record Updates
Last Update Posted (Estimate)
November 30, 2016
Last Update Submitted That Met QC Criteria
November 28, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013L02060
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Digoxin
-
University of California, Los AngelesCompleted
-
Hospital Ana NeryUnknownHeart FailureBrazil
-
Cairo UniversityCompletedAtrial Fibrillation
-
Genzyme, a Sanofi CompanyCompletedHealthy VolunteerUnited States
-
White, Katharine O'Connell, M.D., M.P.H.Society of Family PlanningCompleted
-
GlaxoSmithKlineCompleted
-
Assistance Publique - Hôpitaux de ParisUnknownKaposi' s Sarcoma | Classic Kaposi' s Sarcoma | Endemic Kaposi' s Sarcoma | Lymph Angio ProliferationsFrance
-
University of MonastirCompleted
-
Hoffmann-La RocheCompletedHealthy VolunteerUnited Kingdom
-
PfizerMedivation, Inc.CompletedAlzheimer Disease | Huntington DiseaseUnited States